Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?
作者信息
Laxminarayan Ramanan, John T Jacob
机构信息
Centre for Disease Dynamics, Economics and Policy, Washington DC andSenior Research Scholar, Princeton University, United States.
Retired Professor, Department of Clinical Virology, Christian Medical College, Vellore, India.
出版信息
Indian Pediatr. 2020 Jun 15;57(6):505-507. doi: 10.1007/s13312-020-1844-4. Epub 2020 May 6.
Abstract
摘要
相似文献
1
Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?逐步且可控的群体保护方法是遏制新冠疫情的有效策略吗？
Indian Pediatr. 2020 Jun 15;57(6):505-507. doi: 10.1007/s13312-020-1844-4. Epub 2020 May 6.
2
Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.群体免疫——评估受影响国家遏制新冠疫情所需的群体免疫水平。
J Infect. 2020 Jun;80(6):e32-e33. doi: 10.1016/j.jinf.2020.03.027. Epub 2020 Mar 21.
3
COVID-19-a very visible pandemic.新冠疫情——一场极具影响力的大流行病。
Lancet. 2020 Aug 8;396(10248):e17. doi: 10.1016/S0140-6736(20)31675-5.
4
To achieve "zero covid" we need to include the controlled, careful acquisition of population (herd) immunity.要实现“动态清零”，我们需要纳入可控、审慎地获取群体免疫这一要素。
BMJ. 2020 Sep 9;370:m3487. doi: 10.1136/bmj.m3487.
5
Herd immunity and COVID-19.群体免疫与新冠病毒病
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4064-4065. doi: 10.26355/eurrev_202004_20978.
6
The paramount importance of serological surveys of SARS-CoV-2 infection and immunity.新型冠状病毒2（SARS-CoV-2）感染与免疫血清学调查的至关重要性。
Eur J Epidemiol. 2020 Apr;35(4):331-333. doi: 10.1007/s10654-020-00635-2. Epub 2020 Apr 21.
7
The false promise of herd immunity for COVID-19.新冠病毒群体免疫的虚假承诺。
Nature. 2020 Nov;587(7832):26-28. doi: 10.1038/d41586-020-02948-4.
8
COVID-19: Mitigation or suppression?新冠病毒病：缓解还是抑制？
Arab J Gastroenterol. 2020 Mar;21(1):1-2. doi: 10.1016/j.ajg.2020.04.010.
9
The COVID-19 pandemic and the use of MS disease-modifying therapies.新冠疫情与多发性硬化症疾病修正疗法的使用
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
10
Riding the coronacoaster of uncertainty.在新冠疫情的不确定性中起伏。
Lancet Infect Dis. 2020 Jun;20(6):629. doi: 10.1016/S1473-3099(20)30378-9. Epub 2020 May 15.
引用本文的文献
1
Modelling the first wave of COVID-19 in India.对印度第一波 COVID-19 疫情进行建模。
PLoS Comput Biol. 2022 Oct 24;18(10):e1010632. doi: 10.1371/journal.pcbi.1010632. eCollection 2022 Oct.
2
Reinfection risk of novel coronavirus (COVID-19): A systematic review of current evidence.新型冠状病毒（COVID-19）的再感染风险：当前证据的系统评价
World J Virol. 2020 Dec 15;9(5):79-90. doi: 10.5501/wjv.v9.i5.79.
本文引用的文献
1
Estimating the burden of SARS-CoV-2 in France.估算法国 SARS-CoV-2 的负担。
Science. 2020 Jul 10;369(6500):208-211. doi: 10.1126/science.abc3517. Epub 2020 May 13.
2
Prudent public health intervention strategies to control the coronavirus disease 2019 transmission in India: A mathematical model-based approach.印度控制 2019 年冠状病毒病传播的谨慎公共卫生干预策略：基于数学模型的方法。
Indian J Med Res. 2020;151(2 & 3):190-199. doi: 10.4103/ijmr.IJMR_504_20.
3
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.严重急性呼吸综合征冠状病毒 2 特异性抗体反应在冠状病毒疾病患者中。
Emerg Infect Dis. 2020 Jul;26(7):1478-1488. doi: 10.3201/eid2607.200841. Epub 2020 Jun 21.
4
High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2.高传染性和严重急性呼吸综合征冠状病毒 2 的快速传播。
Emerg Infect Dis. 2020 Jul;26(7):1470-1477. doi: 10.3201/eid2607.200282. Epub 2020 Jun 21.
5
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.中国浙江 36 例 2019 冠状病毒病（COVID-19）患儿的临床和流行病学特征：一项观察性队列研究。
Lancet Infect Dis. 2020 Jun;20(6):689-696. doi: 10.1016/S1473-3099(20)30198-5. Epub 2020 Mar 25.
6
Covid-19: risk factors for severe disease and death.新冠病毒病：重症和死亡的风险因素
BMJ. 2020 Mar 26;368:m1198. doi: 10.1136/bmj.m1198.
7
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).大量未记录的感染使新型冠状病毒（SARS-CoV-2）迅速传播。
Science. 2020 May 1;368(6490):489-493. doi: 10.1126/science.abb3221. Epub 2020 Mar 16.
8
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.感染患者上呼吸道标本中的新型冠状病毒2型病毒载量
N Engl J Med. 2020 Mar 19;382(12):1177-1179. doi: 10.1056/NEJMc2001737. Epub 2020 Feb 19.
9
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus.中东呼吸综合征冠状病毒抗体的持续性
Emerg Infect Dis. 2016 Oct;22(10):1824-6. doi: 10.3201/eid2210.160706. Epub 2016 Oct 15.
10
Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance.SARS患者抗SARS冠状病毒抗体的动态变化及其临床意义
Respirology. 2006 Jan;11(1):49-53. doi: 10.1111/j.1440-1843.2006.00783.x.
Zotero 插件